Subject(s)
Adipocytes/ultrastructure , Fatty Acids/analysis , Inclusion Bodies/ultrastructure , Panniculitis/diagnosis , Subcutaneous Fat/pathology , Coloring Agents , Crystallization , Histiocytes/pathology , Humans , Inclusion Bodies/chemistry , Infant, Newborn , Male , Necrosis , Panniculitis/pathology , Subcutaneous Fat/chemistryABSTRACT
Keratoacanthoma centrifugum marginatum (KCM) is a rare variant of keratoacanthoma characterized by a progressive peripheral growth with concomitant central healing. We report here a case of multiple KCM of the lower legs in a 48-year-old man. The lesions had progressively evolved over 3 years. They were multiple asymptomatic and confluent annular plaques of 5 to 20 cm, having papulo-nodular with hyperkeratotic and crusted borders and cicatricial center. Within the centers were numerous firm and pigmented minipapules of 1 to 2 mm. The typical clinical aspect, together with characteristic histological features confirmed the diagnosis of KCM. Herein we will highlight the clinical and histological features of KCM, as well as the different effective treatments. We will also briefly discuss KCM among the other types of keratoacanthomas.
Subject(s)
Keratoacanthoma/pathology , Leg Dermatoses/pathology , Administration, Cutaneous , Humans , Keratoacanthoma/drug therapy , Leg Dermatoses/drug therapy , Male , Middle Aged , Tretinoin/therapeutic useSubject(s)
Anti-Infective Agents/adverse effects , Sweet Syndrome/chemically induced , Sweet Syndrome/pathology , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Adrenal Cortex Hormones/therapeutic use , Biopsy , Child , Dermis/pathology , Epidermis/pathology , Humans , Male , Sweet Syndrome/drug therapyABSTRACT
Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole. The aim of our study is to determine the efficiency and the tolerance of the fluconazole (Funzol) managed to the dose of 150 mg per week in the treatment of onychomycosis. It is a multicentric and prospective study done to different department of dermatology in Tunisia. Are included adult patients with clinical and mycologic documented onychomycosis. They are treated during 12 to 24 weeks for the fingernail and 24 to 36 weeks for the toenail. The assessment of the efficiency and the tolerance of the drug was clinic and biologic. During this survey, 86 patients are included, 55 female and 31 male with mean age of 43.5 years. Onychomycosis seat to hands in 30 cases (34.8%) with a predominance of Candida species (73%), to toes in 68 cases (79%) witch due in 85% of cases to dermatophytic agent (85%). At 6 months, clinical cure rate is observed in 51% of cases. After 9 months, at the end of therapy, 84% of patients were judged clinical successes and culture was negative in 82% of cases. Some minimal secondary effects are signalled in 11% of cases to 6 weeks and 10% to 12 weeks not justifying the stop of the treatment. So this study confirms the efficiency and the good tolerance of fluconazole in the treatment of onychomycosis.
